Xarelto 15 mg 42 tablets

Tradename

Xarelto

Xarelto

Compound:

rivaroxaban (micronized) 15 mg

Auxiliary components:

microcrystalline cellulose, croscarmellose sodium, hypromellose 5 cP (hydroxypropyl methylcellulose 2910), lactose monohydrate, magnesium stearate, sodium lauryl sulfate.

Properties

Rivaroxaban is a highly selective direct factor Xa inhibitor with relatively high oral bioavailability. Activation of factor X to form factor Xa (FXa) via intrinsic and extrinsic pathways plays a central role in the coagulation cascade. FXa directly converts prothrombin to thrombin via the prothrombinase complex, and this reaction ultimately leads to fibrin clot formation and thrombin activation of platelets. Due to the amplification nature of the coagulation cascade, one factor Xa molecule promotes the formation of more than 1000 thrombin molecules.

Indications

— prevention of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation;

-treatment of deep vein thrombosis and pulmonary embolism and prevention of recurrence of DVT and PE.

Mode of application:

Contraindications

— hypersensitivity to rivaroxaban or any auxiliary components of the drug;

— clinically significant active bleeding;

— injuries or conditions associated with an increased risk of major bleeding;

Side effects

From the blood and lymphatic system:

Anemia (including relevant laboratory parameters).

From the immune system:

Storage

Store at a temperature not exceeding 30 degrees.

Package:

The cardboard box contains 42 tablets, paper instructions.